Abnormal overexpression of c-Myc facilitates cancer development and progression by promoting cell proliferation, metabolic adaptation and suppressing the antitumor immune response [4–7], suggesting c-Myc as an attractive target for anti-cancer therapy. The gene discussed is MYC; the disease is cancer.